- Home
- COLL vs EOI Comparison
COLL vs EOI Comparison
Compare COLL & EOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- EOI
- Stock Information
- Founded
- COLL 2002
- EOI 2004
- Country
- COLL United States
- EOI United States
- Employees
- COLL N/A
- EOI N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- EOI Finance/Investors Services
- Sector
- COLL Health Care
- EOI Finance
- Exchange
- COLL Nasdaq
- EOI Nasdaq
- Market Cap
- COLL 910.2M
- EOI 827.9M
- IPO Year
- COLL 2015
- EOI N/A
- Fundamental
- Price
- COLL $29.05
- EOI $18.42
- Analyst Decision
- COLL Strong Buy
- EOI
- Analyst Count
- COLL 5
- EOI 0
- Target Price
- COLL $43.60
- EOI N/A
- AVG Volume (30 Days)
- COLL 438.9K
- EOI 83.6K
- Earning Date
- COLL 05-08-2025
- EOI 01-01-0001
- Dividend Yield
- COLL N/A
- EOI 7.19%
- EPS Growth
- COLL 43.56
- EOI N/A
- EPS
- COLL 1.86
- EOI N/A
- Revenue
- COLL $631,449,000.00
- EOI N/A
- Revenue This Year
- COLL $20.00
- EOI N/A
- Revenue Next Year
- COLL $3.93
- EOI N/A
- P/E Ratio
- COLL $15.63
- EOI N/A
- Revenue Growth
- COLL 11.41
- EOI N/A
- 52 Week Low
- COLL $27.28
- EOI $14.36
- 52 Week High
- COLL $42.29
- EOI $18.88
- Technical
- Relative Strength Index (RSI)
- COLL 43.65
- EOI 32.24
- Support Level
- COLL $29.01
- EOI $18.31
- Resistance Level
- COLL $30.53
- EOI $18.99
- Average True Range (ATR)
- COLL 0.88
- EOI 0.35
- MACD
- COLL -0.01
- EOI 0.00
- Stochastic Oscillator
- COLL 20.97
- EOI 18.14
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.